Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812945 | 1.00 | ADRB3 (0.43) | ADRB3ADRB1OPRK1KDM4E | |
| SCHEMBL4073010 | 1.00 | ADRB3 (0.43) | ADRB3ADRB1OPRK1KDM4E | |
| SCHEMBL13799343 | 1.00 | ADRB3 (0.43) | ADRB3ADRB1OPRK1KDM4E | |
| SCHEMBL7052344 | 1.00 | ADRB3 (0.43) | ADRB3ADRB1OPRK1KDM4E | |
| SCHEMBL13799342 | 1.00 | ADRB3 (0.43) | ADRB3ADRB1OPRK1KDM4E | |
| Hydrochloric Acid SCHEMBL7056385 | 0.99 | ADRB3 (0.43) | ADRB3ADRB1OPRK1KDM4E | |
| SCHEMBL7058117 | 0.94 | ADRB3 (0.44) | ADRB3ADRB1OPRK1 | |
| SCHEMBL7058116 | 0.94 | ADRB3 (0.44) | ADRB3ADRB1OPRK1 | |
| SCHEMBL7056462 | 0.90 | ADRB3 (0.44) | ADRB3ADRB1KDM4E | |
| SCHEMBL8076934 | 0.90 | ADRB3 (0.44) | ADRB3ADRB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1806335-A1 | METHOD FOR PRODUCING PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | claimed |
| CN-105579057-A | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3 ADRENERGIC RECEPTOR AGONIST | ALLERGAN INC | 2016-05-11 | — | — | CN | disclosed |
| US-7544841-B2 | Production method of phenylethanolamine compound, and its intermediate | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544841-B2 | Production method of phenylethanolamine compound, and its intermediate | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544841-B2 | Production method of phenylethanolamine compound, and its intermediate | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-09 | — | — | US | disclosed |
| CN-101212985-A | Kinin antagonists for treating bladder dysfunction | JERINI AG (DE) | 2008-07-02 | — | — | CN | disclosed |
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1806335-A1 | METHOD FOR PRODUCING PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806335-A1 | METHOD FOR PRODUCING PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
| CN-1791399-A | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS INC (US) | 2006-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | PNMT, COMT, CYP2E1 | ADRB3 4/4885ADRB1 7/4885OPRK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.